论文部分内容阅读
目的 探讨Ⅰ期乳癌患者原发癌的nm2 3表达及其与骨髓微小癌转移 (BMM )的关系 ,方法 以抗上皮细胞膜及nm 2 3 H1单克隆抗体为探针 ,应用免疫组化技术 ,对 5 2例Ⅰ期乳癌患者进行BMM及乳癌原发灶nm2 3表达进行检测。结果 在Ⅰ期乳癌中 ,19 2 %(10 / 5 2 )存在BMM ;在低分化乳癌组中 ,BMM的阳性率 (35 0 % ,7/ 2 0 )明显高于高分化组(9 3 % ,3/ 32 ) (P <0 .0 5 )。在BMM阳性组中 ,nm2 3表达水平 (2 0 0 % ,2 / 10 )显著低于BMM阴性组 (5 9 5 % ,2 5 / 42 ) (P <0 .0 5 )。结论 检测nm 2 3表达可为判断Ⅰ期乳癌有无血道转移提供依据
Objective To investigate the expression of nm23 in primary breast cancer in stage I breast cancer and its relationship with bone marrow micro-metastasis metastasis (BMM). The method was based on anti-epithelial cell membrane and monoclonal antibody (nm 2 3 H1) as immunohistochemical technique. The expression of nm23 in BMM and primary breast cancer was detected in 52 patients with stage I breast cancer. Results In stage I breast cancer, BMM was present in 192% (10/52); in the poorly differentiated breast cancer group, the positive rate of BMM (350%, 7/20) was significantly higher than in the well-differentiated group (93%). , 3/32) (P <0. 0 5). In the BMM positive group, the nm2 3 expression level (200%, 2 / 10) was significantly lower than the BMM-negative group (5.95%, 2 5 / 42) (P <0.05). Conclusion Detecting the expression of nm 2 3 can provide the basis for judging whether there is blood metastasis in stage I breast cancer